[EN] MAGNETODYNAMIC ACTIVATION OF 13C-ACYL ISONIAZID AND ISONIAZID AND ETHIONAMIDE DERIVATIVES [FR] ACTIVATION MAGNÉTODYNAMIQUE DE 13C-ACYL-ISONIAZIDE ET DE DÉRIVÉS D'ISONIAZIDE ET D'ÉTHIONAMIDE
The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
The invention relates to amidic oxotetrahydro-2H-furo[3.2-b]pyrrol-4(5H)-yl) derivatives as dual CatS/K inhibitors, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION
申请人:Northwestern University
公开号:US20160214969A1
公开(公告)日:2016-07-28
Disclosed are new small molecules and the uses thereof for inhibiting superoxide dismutase (SOD) expression. Also disclosed are pharmaceutical compositions comprising the small molecule inhibitors which may be administered in methods of treating diseases or disorders associated with elevated SOD expression or activity, including neurological diseases and disorders such as amyotrophic lateral sclerosis (ALS).